B Group, Inc. reported 19 holdings worth US$213M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
B Group, Inc. reported 19 holdings worth US$213M as of Jun 30, 2026. Largest: Adma Biologics Inc, Palisade Bio, Inc. and Nrx Pharmaceuticals, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 19
- Value as reported
- US$213M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Adma Biologics Inc | 3.26M | US$27.3M | 12.8% |
| Palisade Bio, Inc. | 11.4M | US$23.9M | 11.2% |
| Nrx Pharmaceuticals, Inc. | 4.09M | US$16.7M | 7.9% |
| Sensei Biotherapeutics, Inc. | 610K | US$15.3M | 7.2% |
| Taysha Gene Therapies, Inc. | 1.8M | US$12.3M | 5.8% |
| Praxis Precision Medicines, Inc. | 33,237 | US$11.1M | 5.2% |
| Cellectis S.a. | 3.28M | US$9.84M | 4.6% |
| Zai Lab Ltd. | 451K | US$8.56M | 4.0% |
| Oruka Therapeutics, Inc. | 75,000 | US$7.14M | 3.4% |
| Iovance Biotherapeutics, Inc. | 1.5M | US$6.24M | 2.9% |
| Spyre Therapeutics, Inc. | 70,000 | US$6.21M | 2.9% |
| Aura Biosciences, Inc. | 764K | US$5.43M | 2.5% |
| Assembly Biosciences, Inc. | 176K | US$4.83M | 2.3% |
| Bright Minds Biosciences Inc. | 67,500 | US$4.74M | 2.2% |
| Ultragenyx Pharmaceutical Inc. | 135K | US$4.51M | 2.1% |
| Sight Sciences, Inc. | 970K | US$3.66M | 1.7% |
| Foghorn Therapeutics Inc. | 200K | US$976K | 0.46% |
| Apogee Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Replimune Group, Inc. | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |